Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

被引:306
作者
Ahonen, CL
Doxsee, CL
McGurran, SM
Riter, TR
Wade, WF
Barth, RJ
Vasilakos, JP
Noelle, RJ
Kedl, RM
机构
[1] 3M Co, 3M Pharmaceut, Dept Pharmacol, St Paul, MN 55144 USA
[2] Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03756 USA
[3] Dartmouth Coll Sch Med, Dept Surg, Lebanon, NH 03756 USA
关键词
Toll like receptor; TLR7; CD40; CD8; T cell;
D O I
10.1084/jem.20031591
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Toll-like receptors are important in the activation of innate immunity, and CD40 is a molecule critical for many T and B cell responses. Whereas agonists for either pathway have been used as vaccine adjuvants, we show that a combination of Toll-like receptor (TLR)7 and CD40 agonists synergize to stimulate CD8(+) T cell responses 10-20-fold greater than the use of either agonist alone. Antigen-specific CD8+ T cells elicited from combination CD40/TLR,7 treatment demonstrated both lyric activities and interferon (IFN)gamma production and an enhanced secondary response to antigenic challenge. Agonists for TLRs 2/6, 3, 4, and 9 also synergized with CD40 stimulation, demonstrating that synergy with the CD40 pathway is a property of TLR,-derived stimuli in general. The CD8(+) T cell expansion induced by CD40/TLR7 triggering was independent of CD4(+) T cells, IFNgamma, and IL-12 but dependent on B7-mediated costimulation and surprisingly on type 1 IFN. These studies provide the rational basis for the use of TLR, and CD40 agonists together as essential adjuvants to optimize vaccines designed to elicit protective or therapeutic immunity.
引用
收藏
页码:775 / 784
页数:10
相关论文
共 60 条
[1]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]   Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848 [J].
Ahonen, CL ;
Gibson, SJ ;
Smith, RM ;
Pederson, LK ;
Lindh, JM ;
Tomai, MA ;
Vasilakos, JP .
CELLULAR IMMUNOLOGY, 1999, 197 (01) :62-72
[3]   Mammalian Toll-like receptors [J].
Akira, S .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (01) :5-11
[4]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[5]   Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice [J].
Alexopoulou, L ;
Thomas, V ;
Schnare, M ;
Lobet, Y ;
Anguita, J ;
Schoen, RT ;
Medzhitov, R ;
Fikrig, E ;
Flavell, RA .
NATURE MEDICINE, 2002, 8 (08) :878-884
[6]   THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME [J].
ARUFFO, A ;
FARRINGTON, M ;
HOLLENBAUGH, D ;
LI, X ;
MILATOVICH, A ;
NONOYAMA, S ;
BAJORATH, J ;
GROSMAIRE, LS ;
STENKAMP, R ;
NEUBAUER, M ;
ROBERTS, RL ;
NOELLE, RJ ;
LEDBETTER, JA ;
FRANCKE, U ;
OCHS, HD .
CELL, 1993, 72 (02) :291-300
[7]   Cutting edge: Rapid in vivo killing by memory CD8 T cells [J].
Barber, DL ;
Wherry, EJ ;
Ahmed, R .
JOURNAL OF IMMUNOLOGY, 2003, 171 (01) :27-31
[8]   Help for cytotoxic-T-cell responses is mediated by CD40 signalling [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Flavell, RA ;
Miller, JFAP ;
Heath, WR .
NATURE, 1998, 393 (6684) :478-480
[9]   Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848 [J].
Bishop, GA ;
Hsing, Y ;
Hostager, BS ;
Julukar, SV ;
Ramirez, LM ;
Tomai, MA .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5552-5557
[10]   A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory [J].
Bourgeois, C ;
Rocha, B ;
Tanchot, C .
SCIENCE, 2002, 297 (5589) :2060-2063